This Dividend Stock Is Beating the S&P 500 by 170% in 2026
1 extracted signal · 0 resolved · 1 still active
Dividend DiplomatsIndependent analyst profile- Source published
- 03 Nov 2026, 13:00 UTC
- Recorded by Tahlil Plus
- 03 Nov 2026, 16:03 UTC
AI-generated source summary
AbbVie (ABBV) demonstrates strong financial performance, significantly outperforming the S&P 500 year-to-date with a 29% increase compared to the S&P 500's 10.73%. The company has raised its full-year adjusted earnings per share guidance to between $13.95 and $13.99, with total net revenues projected at approximately $67.8 billion. Q4 revenue is forecasted at $18.4 billion, a $1 billion increase from Q3. Key drug Skyrizi and Rinvoq have shown substantial double-digit growth, with revenues rising 22.7% and 23.9% respectively. The company generated $14 billion in free cash flow over the first nine months of 2026. Despite a P/E ratio of 21.08, which is on the higher side for the pharmaceutical industry, the dividend yield stands at 2.47% with a safe payout ratio of 52.04%. The dividend has increased for 13 consecutive years, with a recent 5.2% quarterly increase. The 5-year dividend growth rate is 5.88%. AbbVie's stock has appreciated 151.66% over the last 5 years, indicating strong long-term performance.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
Dividend Diplomats
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.